Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Trabeculectomy bleb needling and antimetabolite administration practices in the UK: a glaucoma specialist national survey

Poster Details

First Author: B.Drury UK

Co Author(s):    K. Mercieca   A. Bhargava   C. Fenerty              

Abstract Details

Purpose:

To evaluate, describe and quantify the diversity in post-operative antimetabolite administration and bleb needling practices amongst glaucoma specialists performing trabeculectomy surgery within the U.K. and Ireland.

Setting:

Manchester Royal Eye Hospital, Machester and Royal Preston Hospital, Preston

Methods:

A cross-sectional online survey was distributed to all consultant glaucoma specialists who are on the United Kingdom & Eire Glaucoma Society (UKEGS) contact list. Participants were asked specific questions about their current practices for post-trabeculectomy antimetabolite administration followed by questions directly related to bleb needling procedures.

Results:

60 consultants completed the survey. Doses of 5-FU varied considerably but 70% used 5mg as standard. Techniques used to reduce corneal toxicity included precipitation with amethocaine (44%) or benoxinate (14%), saline wash (14%) and modified injection technique (8%); 42% of participants did not use a specific strategy to prevent this. Bleb needling was exclusively performed in operating theatre by 56% of respondents. Anti-metabolites used were 5-Fluorouracil (72%) and mitomycin C (22%) with 12% using either of the two substances. Only a minority of participants used viscoelastic (32%) or subconjunctival steroid (42%) as part of their needling technique.

Conclusions:

There is a significantly wide variety of current practices for antimetabolite administration and bleb needling within the UK and Ireland. This may be influenced by a glaucoma surgeon�â�€�™s specific experience and audit results as well as particular clinical set-up, availability of antimetabolite and clinic room space.

Financial Disclosure:

NONE

Back to Poster listing